

Protalix BioTherapeutics, Inc.  
Form 8-K  
June 11, 2012

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): June 11, 2012**

**Protalix BioTherapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

Edgar Filing: Protalix BioTherapeutics, Inc. - Form 8-K

**(State or other jurisdiction  
of incorporation)**

(Commission File Number)

**(IRS Employer  
Identification No.)**

2 Snunit Street  
Science Park, POB 455  
Carmiel, Israel  
(Address of principal executive offices) **(Zip Code)**

20100

**Registrant's telephone number, including area code +972-4-988-9488**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events**

On June 11, 2012, Protalix BioTherapeutics, Inc. issued a press release announcing that it has received a \$25 million milestone payment from Pfizer Inc. as part of the companies' global commercial agreement for ELELYSO™ (taliglucerase alfa). The payment was triggered by the U.S. Food and Drug Administration's approval of ELELYSO for the treatment of type 1 Gaucher disease on May 1, 2012. A copy of the press release is attached hereto as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1 Press release dated June 11, 2012.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTALIX  
BIOTHERAPEUTICS, INC.**

Date: June 11, 2012 By: /s/ David Aviezer  
Name: David Aviezer, Ph.D.  
Title: President and  
Chief Executive Officer